OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI)

I. Raz

P. W.F. Wilson

K. Strojek

I. Kowalska

V. Bozikov

A. K. Gitt

G. Jermendy

B. N. Campaigne

L. Kerr

Z. Milicevic

S. J. Jacober

Stamler

Haffner

Eberly

Stratton

Beckman

Lakka

DECODE Study Group

Meigs

Ceriello

Chiasson

Malmberg

Milicevic

Shimabukuro

Dormandy

English

PubMed

van Leeuwen, Sander S.

Kralj, Slavko

Gerwig, Gerrit J.

Dijkhuizen, Lubbert

Kamerling, Johannis P.

University of Groningen

Structural analysis of bioengineered alpha-D-glucan produced by a triple mutant of the glucansucrase GTF180 enzyme from Lactobacillus reuteri strain 180:Generation of (alpha 1 -&gt; 4) linkages in a native (1 -&gt; 3)(1 -&gt; 6)-alpha-D-glucan

Site-directed mutagenesis of the glucansucrase gtf180 gene from Lactobacillus reuteri strain 180 was used to transform the active site region. The alpha-D-glucan (mEPS-PNNS) produced by the triple mutant V1027P:S1137N: A1139S differed in structure from that of the wild-type alpha-D-glucan (EPS180). Besides (alpha 1--&gt;3) and (alpha 1--&gt;6) linkages, as present in EPS180, mEPS-PNNS also contained (alpha 1--&gt;4) linkages. Linkage analysis, periodate oxidation, and 1D/2D (1)H NMR spectroscopy of the intact mEPS-PNNS, as well as MS and NMR analysis of oligosaccharides obtained by partial acid hydrolysis of mEPS-PNNS afforded a composite model, which includes all identified structural features.</p

ARTS repository - University of Groningen

Proceedings - University of Groningen

Dissertations of the University of Groningen

Site-directed mutagenesis of the glucansucrase gtf180 gene from Lactobacillus reuteri strain 180 was used to transform the active site region. The alpha-D-glucan (mEPS-PNNS) produced by the triple mutant V1027P:S1137N: A1139S differed in structure from that of the wild-type alpha-D-glucan (EPS180). Besides (alpha 1-->3) and (alpha 1-->6) linkages, as present in EPS180, mEPS-PNNS also contained (alpha 1-->4) linkages. Linkage analysis, periodate oxidation, and 1D/2D (1)H NMR spectroscopy of the intact mEPS-PNNS, as well as MS and NMR analysis of oligosaccharides obtained by partial acid hydrolysis of mEPS-PNNS afforded a composite model, which includes all identified structural features

NARCIS 

Structural analysis of bioengineered alpha-D-glucan produced by a triple mutant of the glucansucrase GTF180 enzyme from Lactobacillus reuteri strain 180: Generation of (alpha 1 -> 4) linkages in a native (1 -> 3)(1 -> 6)-alpha-D-glucan

University of Groningen Research Database

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

al.: 10-Year follow-up of intensive glucose control in type 2 diabetes.

Association of glycaemia with macrovascularandmicrovascularcomplications of type 2 diabetes (UKPDS 35): prospective observational study.

atherosclerosis: epidemiology, pathophysiology and management.

Diabetes, other risk factors, and 12-yr cardiovascularmortalityformenscreened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444,

Effectofatorvastatinandirbesartan,alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inﬂammation in type 2 diabetic patients. Circulation 111:2518–2524,

et al.: Effects of dietary composition on postprandial endothelial function and adiponectin concentrations in healthy humans: a crossover controlled study.

Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850,

Glucose control and vascular complications in veterans with type 2 diabetes.

Glucose tolerance and cardiovascular mortality: comparison of fasting and2-hourdiagnosticcriteria.ArchIntern Med 161:397–405,

Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D) study design.

Impact of diabetes and incident nonfatal cardiovascular disease on 18-year mortality. Diabetes Care 26:848–854,

Insulin vs. strict blood glucose control to achieve a survival beneﬁt after AMI? Eur Heart

Intense metabolic control by means of insulin in patients with diabetes mellitus andacutemyocardialinfarction(DIGAMI 2):effectsonmortalityandmorbidity.Eur Heart J 26:650–661,

Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 27:2456–2462,

Postprandial glucose and not triglyceride concentrations are associated with carotid intima media thickness in women with normal glucose metabolism: the Hoorn prandial study. Atherosclerosis 196:712–719,

Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1–7,

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus:

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214–219,

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Similarityoftheimpactoftype1andtype 2 diabetes on cardiovascular mortality in middle-aged subjects.

The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type

The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.